Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00527735 · ClinicalTrials.gov registry record · Phase 2
Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 334
- Enrollment target
NCT00527735 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 334 participants.
The verdict
NCT00527735, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 334 participants
- Enrollment target
Study Summary
The purpose of the study is to determine whether ipilimumab given with paclitaxel/carboplatin has clinical benefit when compared with paclitaxel/carboplatin alone in patients with previously untreated lung cancer.
Interventions
- DRUG Carboplatin
- DRUG Placebo
- DRUG Ipilimumab
- DRUG Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 334 participants |
| Start Date | 2008-02 |
| Est. Completion | 2011-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00527735
The ClinicalTrials.gov registry entry for NCT00527735 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 334 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT00527735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00527735 about?
NCT00527735 is a clinical study titled "Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)". The purpose of the study is to determine whether ipilimumab given with paclitaxel/carboplatin has clinical benefit when compared with paclitaxel/carboplatin alone in patients with previously untreated lung cancer.
What is the current status of trial NCT00527735?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 334 participants. The study started on 2008-02. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00527735?
The interventions under investigation include: Carboplatin (DRUG), Placebo (DRUG), Ipilimumab (DRUG), Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00527735?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.